Clinical Trial

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer after taxane failure.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2026-06 -> 2026-01-13 2026-07-24
minor Completion pushed: 2026-06 -> 2027-12 2026-07-24
Trial Details
NCT Number NCT06382142
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Triple-Negative Breast Cancer
Enrollment 418 participants
Start Date 2024-06-21
Primary Completion 2026-01-13 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23